GMA
The category is moving from a simple “weight-loss support” narrative to a harder question: how can nutritional adequacy and function be supported when food intake falls? The answer belongs to a system—dietary assessment, protein quality, resistance exercise, tolerability and clinical oversight—not to a single fashionable ingredient.
A new category is forming. Its boundaries are not yet stable.
The July 2026 EASO, EFAD and ECPO consensus statement frames nutrition, resistance exercise and medical nutrition as central elements in care with incretin-based therapies. For industry, this is a strong signal: products will be judged on nutritional density, usability and evidence quality. It is not evidence that a supplement improves drug response or prevents adverse outcomes.
Lean mass can decline. That is not the same as proven muscle loss.
A 2026 meta-analysis of seven randomised trials and 821 participants estimated an absolute reduction in lean mass during treatment, with substantial heterogeneity between studies and interventions. Fat mass decreased more than lean mass and relative body composition often improved. Fat-free mass, skeletal muscle mass and muscle strength are related measures, but they are not interchangeable.
FAT-FREE MASS ≠ SKELETAL MUSCLE ≠ MUSCLE FUNCTION
Less appetite makes every bite carry more responsibility.
Small portions, food aversion, nausea or early satiety can reduce protein, fluid and micronutrient intake. The credible design question is therefore not “what mimics GLP‑1?”, but “what nutritional job remains difficult to perform with ordinary food, in this format, for this user?”.
Design for nutritional density, not for therapeutic imitation.
Protein quality
Useful amount, amino-acid profile, serving volume and tolerance must coexist.
Micronutrient density
Correct a documented or plausible intake gap; avoid decorative premixes and universal deficiency language.
Format & tolerance
Low-volume servings, taste, texture and gastrointestinal burden can determine real use.
Fibre & biotics
Potentially relevant, but tolerance, hydration and individual symptoms require caution.
Creatine & function
Biologically plausible for muscle support; direct evidence in GLP‑1 users remains limited.
Botanicals
High storytelling potential, but also the highest risk of overclaiming, interaction and category confusion.
Opportunity is not the same as direct evidence.
The matrix is an editorial R&D map, not a recommendation or efficacy score.
| Category | Rationale in weight loss | Direct GLP‑1 evidence | Formulation relevance | Claim / regulatory risk |
|---|---|---|---|---|
| Protein / EAA | High | Moderate | High | Low–moderate |
| Micronutrients | Moderate | Low | High | Low |
| Creatine | Moderate | Low | Moderate | Moderate |
| Fibre / prebiotics | Moderate | Low | Moderate | Moderate |
| Botanicals | Variable | Very low | Variable | High |
The fastest route to the market may be the fastest route to an indefensible claim.
In Europe, communication must remain within authorised nutrition and health claims and the actual characteristics of the product. “Supports protein intake” and a statement implying treatment of medication-related muscle loss are not variants of the same message. Companion positioning must never suggest replacing, potentiating or managing prescription therapy without an appropriate evidence and regulatory basis.
Seven questions before opening a GLP‑1 project.
- 01
Which nutritional problem is being addressed, and for whom?
- 02
Is the endpoint intake, body composition, function, tolerance or adherence?
- 03
Is evidence direct in GLP‑1 users or extrapolated from another context?
- 04
Can the useful amount fit into a tolerated serving?
- 05
Which clinical, nutritional and medication interactions require review?
- 06
Which authorised claims can genuinely describe the finished product?
- 07
What study would be needed to move from rationale to product evidence?
This dossier is intended for professional information only. It does not constitute medical advice, a recommendation concerning prescription medicines, a safety assessment, legal advice or a regulatory opinion. Any application must be reviewed against the specific product, population, market and evidence dossier.